Tumour-Induced Osteomalacia (TIO) is a rare and debilitating condition that affects the bones, causing them to become weak and brittle. The condition is caused by a benign tumour that secretes a hormone called phosphaturic hormone, which interferes with the normal process of bone formation. This results in a deficiency of calcium in the bones and leads to osteomalacia.
The Tumour-Induced Osteomalacia Market is estimated to grow in the coming years due to the increasing prevalence of TIO and the increasing demand for effective treatments. The market is segmented based on diagnosis, treatment, and geography.
Diagnosis of TIO involves a series of tests, including X-rays, CT scans, and bone density tests. Treatment options for TIO include surgical removal of the tumour, drug therapy, and rehabilitation. The most commonly used drugs for TIO are bisphosphonates, which help to reduce the secretion of the phosphaturic hormone and prevent further bone loss.
The Tumour-Induced Osteomalacia Market is expected to grow due to the increasing awareness of the condition and the increasing demand for effective treatments. The market is expected to be driven by the increasing prevalence of TIO and the increasing demand for effective treatments.
In conclusion, the Tumour-Induced Osteomalacia Market is expected to grow in the coming years due to the increasing prevalence of TIO and the increasing demand for effective treatments. The market is expected to be driven by the increasing awareness of the condition and the increasing demand for effective treatments.
Worldwide revenue from the tumour-induced osteomalacia market reached US$ 111,372.2 thousand in 2021, with the global market estimated to move ahead at a value CAGR of 2.8% to reach US$ 176,483.9 thousand by the end of 2032.
Competitive Landscape
Leading pharmaceutical companies are putting strong emphasis on partnerships to broaden their product offerings and capture a higher share of the market for drugs used for the diagnosis, treatment, and evaluation of bone diseases.
To maintain a competitive edge in the market, manufacturers in emerging nations are continually investing in research and development activities to design, develop, and introduce new pharmaceuticals and drug combinations, in addition to upgrading their product portfolios.
For instance:
- In July 2020, Ultragenyx and Kyowa Kirin announced that they had received U.S. FDA approval for Crysvita® (burosumab) for the treatment of TIO.
- In August 2021, Carbogen Amcis revealed expansion plans in Switzerland and France.